The family impact of childhood atopic dermatitis: the Dermatitis Family Impact questionnaire

Lawson, Victor G.; Lewis‐Jones, M.S.; Finlay, A.Y.; Reid, Peter; Owens, R. Glynn

doi:10.1046/j.1365-2133.1998.02034.x

Cited by 366 publications

(466 citation statements)

References 10 publications

Supporting

Mentioning

440

Contrasting

Unclassified

Order By: Relevance

“…Atopik dermatitli çocukların ebeveynleri için pek çok hastalığa özgü ölçek geliştirilmiştir 18,20 . Atopik dermatitli çocukların aileleri sağlıklı çocukların ailelerinden daha düşük yaşam kalitesine sahiptirler ve orta ile şiddetli atopik dermatitli bir çocuğun bakımını üstlenmenin insüline bağımlı diyabetes mellituslu bir çocuğun bakımını yapmaktan daha stresli olduğu gösterilmiştir 13,14,19 . Herhangi bir deri hastalığı olan hastaların aileleri ve ebeveynleri için geliştirilmiş genel dermatolojiye özgü tek ölçü aracı "Family Dermatology Life Quality Index (FDLQI)"dir.…”

Section: Discussionunclassified

Dermatolojik hastalıklara özgü aile etki ölçeği geliştirilmesi; geçerlik ve güvenirlik çalışması

Turan¹,

Gürel²,

Erdemir³

et al. 2014

TURKDERM

View full text Add to dashboard Cite

Background and Design: Skin diseases have negative impacts on patients' psychological well being, social life and daily activities. Close family members are also indirectly or directly affected with respect to care and treatment of patients. In particular, chronic skin diseases reduce the quality of life of family members who have close relationship with the patient. This study is aimed to determine how family members of patients are affected and to develop and validate a specific instrument for the Turkish population in order to use for measuring the impact of dermatological diseases. Materials and Methods: The Dermatological Diseases Family Impact Scale (DeFIS) has been prepared on the basis of data obtained from 176 family members of patients and the DeFIS was filled by close family members of 202 patients with chronic dermatosis aged between 18 and 76 years. The family members also responded to the General Health Questionnaire-12 (GHQ-12), whereas patients responded to the Turkish dermatology quality of life instrument (TDQL). Additionally, 202 healthy participants comprised a control group that responded to the DeFIS and GHQ-12. Disease severity was assessed by physicians and relatives of patients on the 5-point Likert scale. The DeFIS was developed into its final form based on the feedback received from family members of patients, dermatologists and psychologists. Psychometric evaluation was done for family members of patients who responded to the DeFIS and GHQ-12 as well as for patients who responded to the TDQL.

show abstract

Section: Discussionunclassified

Dermatolojik hastalıklara özgü aile etki ölçeği geliştirilmesi; geçerlik ve güvenirlik çalışması

Turan¹,

Gürel²,

Erdemir³

et al. 2014

TURKDERM

View full text Add to dashboard Cite

show abstract

“…На родителей накладываются дополнительные обязанности -им необходимо тратить огромное коли-чество времени на уход за ребенком, что в свою оче-редь негативно влияет на социальное и эмоциональное благополучие семьи в целом. В ряде работ доказано, что родителям детей, страдающих АтД, психологическая поддержка требуется в большем объеме, чем семьям с ребенком, больным сахарным диабетом [11][12][13].…”

Section: классификацияunclassified

Chronic Itching Dermatosis in Children: Modern Methods of Treatment and Efficient Termination of Subjective Complaints

et al. 2016

View full text Add to dashboard Cite

“…(see Measurement of costs and outcomes to estimate cost-effectiveness). l Health-related QoL at baseline, 6 and 8 months: Dermatitis Family Impact (DFI) 359 will be used to assess the impact on the whole family, as this scale can be applied to all participants regardless of their age. EQ-5D-3L 360 will provide a utility measure for the main carer and age-appropriate utility measures will provide an eczema-specific utility score 212 and a general health utility score [Children's Health Utility Index 9 dimensions (CHU-9D)].…”

Section: Secondary Outcomesmentioning

confidence: 99%

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Kim

Batchelor

Bath‐Hextall

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

Programme Grants for Applied ResearchISSN 2050-4322 (Print) ISSN 2050-4330 (Online) This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: nihredit@southampton.ac.ukThe full PGfAR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/pgfar. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Programme Grants for Applied Research journalReports are published in Programme Grants for Applied Research (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors. Programme Grants for Applied Research programmeThe Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was set up in 2006 to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. The Programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director.The programme is a national response mode funding scheme that aims to provide evidence to improve health outcomes in England through promotion of health, prevention of ill health, and optimal disease management (including safety and quality), with particular emphasis on conditions causing significant disease burden.For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-forapplied-research.htm This reportThe research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0407-10177. The contractual start date was in September 2008. The final report began editorial review in April 2014 and was accepted for publication in April 2016. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, CCF, NETSCC, PGfAR or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, ...

show abstract

The family impact of childhood atopic dermatitis: the Dermatitis Family Impact questionnaire

Cited by 366 publications

References 10 publications

Dermatolojik hastalıklara özgü aile etki ölçeği geliştirilmesi; geçerlik ve güvenirlik çalışması

Dermatolojik hastalıklara özgü aile etki ölçeği geliştirilmesi; geçerlik ve güvenirlik çalışması

Chronic Itching Dermatosis in Children: Modern Methods of Treatment and Efficient Termination of Subjective Complaints

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Contact Info

Product

Resources

About